Patents Examined by David Lukton
  • Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
    Patent number: 9150609
    Abstract: A process for the synthesis of copolymer-1 composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine for the treatment of multiple sclerosis. The molecular weight of copolymer-1 is between 8-19 KDa. The process is initiated by supported dialkyl amine. The copolymer-1 of the invention has acid content of less than 1%.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: October 6, 2015
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventor: Baijayantimala Garnaik
  • RNA targeting compounds and methods for making and using same
    Patent number: 9150612
    Abstract: Disclosed are RNA targeting compounds having the formula: wherein j is an integer from 1 to 100; each i is the same or different and is zero or an integer from 1 to 100; each Z1 represents the same or different linking moiety; each R1 is the same or different and represents an alkyl group or an aryl group; each Q1 represents the same or different RNA binding ligand; Q2 is an alkyl group; Q3 is a halogen, an alkyl group, an aryl group, or an amine. Also disclosed are RNA targeting compounds that include a polymer backbone and two or more pendant RNA binding ligands that are bound to the polymer backbone. Methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed, as are compounds that can be used to prepare the subject RNA targeting compounds.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: October 6, 2015
    Assignee: The Research Foundation of State University of New York
    Inventor: Matthew D. Disney
  • Charge reversible polymers
    Patent number: 9145472
    Abstract: Described are charge reversible polymers, peptides and their resulting colloidal particles, comprising polymers and peptides having primary and secondary amines that are protected as easily hydrolysable amides. The amides are charge-reversible such that at neutral pH they are negatively charged but become positively charged at pH less than 6 and thus are relatively stable at neutral pH but quickly hydrolyze at pH below 6. Incorporating a drug in a micelle or a polymer comprised of the charge-reversible polymers or peptides provides a drug carrier for delivering the drug preferentially to the solid tumor or other targeted cells.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: September 29, 2015
    Assignee: Wyoming Research Products Center
    Inventors: Youqing Shen, Peisheng Xu
  • High-density lipoprotein coated medical devices
    Patent number: 9138513
    Abstract: Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: September 22, 2015
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventor: Ni Ding
  • Use of peptides for promoting wound healing
    Patent number: 9133238
    Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: September 15, 2015
    Assignee: Rapid Pathogen Screeening, Inc.
    Inventors: Johannes Gerhardus Maria Bolscher, Arie Van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem Van't Hof, Kamran Nazmi, Petronella Adriana Maria Van Den Keijbus
  • Cyclic depsipeptides
    Patent number: 9127044
    Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: September 8, 2015
    Assignee: NOVARTIS AG
    Inventors: Philipp Krastel, Brigitta-Maria Liechty, Josef Gottfried Meingassner, Esther Schmitt, Erwin Paul Schreiner
  • Method of inhibiting bacterial growth and biofilm formation with natural quorum sensing peptides
    Patent number: 9127045
    Abstract: Methods for selectively manipulating a growth rate of a selected bacterium comprising the step of contacting the selected bacterium with a predetermined amount of a quorum sensing molecule to affect a change in the growth rate of the selected bacterium, wherein the quorum sensing molecule is species specific, and the change in the growth rate is dependent on the amount of quorum sensing molecule in a dose-dependent fashion. Also provided are methods for treating or protecting against bacterial infections by utilizing the dose-dependent response of bacterial quorum sensing systems. The methods can be applied to a wide range of bacteria species including Streptococci, Staphylococci, and Bacilli. Compositions, medicaments and oral formulations for use with the methods are also disclosed.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: September 8, 2015
    Assignees: UNIVERSITY OF SOUTHERN CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Steven D. Goodman, Olga Kay, Wenyuan Shi, Fengxia Qi
  • Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
    Patent number: 9126997
    Abstract: Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a proteasome inhibitor and administering to the patient in need thereof a glucocorticoid receptor (GR) agonist, either before, concurrently with, or after the proteasome inhibitor is administered.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: September 8, 2015
    Assignee: Northwestern University
    Inventors: Irina Budunova, Alexander Yemelyanov
  • Functional enhancement of antimicrobials
    Patent number: 9120861
    Abstract: The present invention provides methods for adding functional hydrophobic, charge, polar, and other structural groups on antimicrobial compounds for enhancing the physicochemical properties of the antimicrobial compounds, thereby creating novel antimicrobial analogs with enhanced functions.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: September 1, 2015
    Assignee: Mississippi State University
    Inventor: James Leif Smith
  • Agent derived from tortoise spleen stimulating mammalian hemopoiesis
    Patent number: 9120843
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: September 1, 2015
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev
  • Proteinase K inhibitors, methods and compositions therefor
    Patent number: 9114104
    Abstract: The synthesis, biological evaluation, and molecular modeling of alkoxysuccinyl-peptidyl-haloalkyl ketones for use as proteinase K inhibitors are described. Sample preparation processes for in situ RNA or DNA analysis using such inhibitors, methods and compositions therefor are provided.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: August 25, 2015
    Assignee: Life Technologies Corporation
    Inventors: Anilkumar R. Kore, Muthian Shanmugasundaram
  • Insulin-oligomer conjugates, formulations and uses thereof
    Patent number: 9102758
    Abstract: An insulin conjugate is disclosed in which insulin is coupled to a modifying moiety of the formula X—R1—Y-PAG-Z—R2 wherein X, Y, and Z are linking groups, R2 is a capping group, and PAG is a carbon chain that incorporates one or more alkylene glycol moieties.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: August 11, 2015
    Assignee: BIOCON LIMITED
    Inventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Monica E. Puskas, Nnochiri N. Ekwuribe
  • Cation complexes of insulin compound conjugates, formulations and uses thereof
    Patent number: 9101596
    Abstract: An insulin compound coupled to a modifying moiety having a formula: —X—R1—Y-PAG-Z—R2??(Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R1 or R2 is a lower alkyl, optionally including a carbonyl group, and when R1 is a lower alkyl, R2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: August 11, 2015
    Assignee: BIOCON LIMITED
    Inventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Monica Puskas, Nnochiri N. Ekwuribe
  • Mutant double cyclized receptor peptides inhibiting ?-adrenoceptor antibodies
    Patent number: 9062095
    Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-?-adrenergic receptor antibodies like anti-?-adrenergic receptor antibodies.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: June 23, 2015
    Assignee: JULIUS-MAXIMILIANS-UNIVERSTITAT-WURZBURG
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Viacheslav Nikolaev
  • Somatostatin analogues
    Patent number: 9035021
    Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: May 19, 2015
    Assignee: Novartis AG
    Inventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
  • Glucose-dependent insulinotropic peptide analogs
    Patent number: 9023986
    Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 5, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Peptide compositions and therapeutic uses thereof
    Patent number: 9018352
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 28, 2015
    Assignee: Allegro Pharmaceuticals, Inc.
    Inventors: Michael J. Mackel, John Park
  • Method for the preparation of cyclopeptides
    Patent number: 9006391
    Abstract: The present invention relates to a method for preparing cyclopeptides by means of protection with a substituted boronic acid. The present invention also discloses novel boronate esters of cyclopeptides of general formula (8).
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: April 14, 2015
    Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.
    Inventors: Robertus Mattheus De Pater, Dhiredj Chandre Jagesar, Thomas Van Der Does
  • Heat-stable, aqueous lactoferrin composition and its preparation and use
    Patent number: 8999923
    Abstract: The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: April 7, 2015
    Assignee: Campina Nederland Holding B.V.
    Inventors: Linqiu Cao, Hans Maas
  • Approach to treat intraocular hypertension
    Patent number: 9000125
    Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: April 7, 2015
    Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische